Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by Thomas Jefferson University
Sponsor:
Collaborators:
GlaxoSmithKline
Novartis
Information provided by (Responsible Party):
Thomas Jefferson University
ClinicalTrials.gov Identifier:
NCT01458366
First received: September 26, 2011
Last updated: June 3, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2017
  Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)